Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump ...

The initiative, which will start with monoclonal antibodies, is the first big regulatory shift from the FDA since Martin ...

Shares in many large drugmakers initially fell Wednesday on the president's threat, only to rebound later when he announced a ...

Universities are waiting cautiously as the agency's unilateral plan to cut billions of research support dollars has already ...

The bispecific antibody helped people with small cell lung cancer live longer, Amgen said. Elsewhere, J&J shared new autoimmune drug data and Alzheon reported an Alzheimer’s drug failure.

Experts say the layoffs are already causing issues in drug development — and things may get far worse without critical ...

More than three-quarters of private biotech investment tracked by BioPharma Dive between January and March was distributed ...

Drug company shares, which had sunk on comments by Trump that pharma duties would be coming soon, rallied along with the ...

Provider groups and health systems warn tariffs will test healthcare’s fragile supply chain, threatening to create ...

The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...

There will be a ChatGPT moment for biotechnology,” a bipartisan commission wrote in the new report, which calls for the U.S.

Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.